2010
DOI: 10.1177/1533317510367486 View full text |Buy / Rent full text
|
|

Abstract: Rivastigmine has been shown to improve cognition in patients with Parkinson's disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for ADAS-cog item scores and for 3 cognitive domain scores. A total of 362 patients were randomized to 3 t… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
2
2
1
0
13
0

Year Published

2013
2013
2017
2017

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

0
13
0
Order By: Relevance
“…Rivastigmine is FDA approved for PD dementia, based on a study of 541 patients with mild to moderate dementia that used the Alzheimer's Disease Assessment Scale—cognitive subscale as the primary outcome measure . In a substudy, rivastigmine was shown to have a benefit on the DRS‐2, specific attention measures, executive abilities, and memory, language, and praxis subtests of the Alzheimer's Disease Assessment Scale—cognitive subscale . Some evidence indicated that rivastigmine's effect was greatest in patients with baseline comorbid hallucinations, which in part may be explained by increased severity of cognitive impairment in this subgroup …”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Rivastigmine is FDA approved for PD dementia, based on a study of 541 patients with mild to moderate dementia that used the Alzheimer's Disease Assessment Scale—cognitive subscale as the primary outcome measure . In a substudy, rivastigmine was shown to have a benefit on the DRS‐2, specific attention measures, executive abilities, and memory, language, and praxis subtests of the Alzheimer's Disease Assessment Scale—cognitive subscale . Some evidence indicated that rivastigmine's effect was greatest in patients with baseline comorbid hallucinations, which in part may be explained by increased severity of cognitive impairment in this subgroup …”
Section: Discussionmentioning
“…Compared with placebo, rivastigmine also demonstrated significant benefits on ADCS-ADL ( P =0.02), NPI-10 ( P =0.02), MMSE ( P =0.03), cognitive drug research power of attention tests ( P =0.009), Delis–Kaplan executive function system verbal fluency test ( P <0.001), and the TPC drawing test ( P =0.02) at week 24. In the retrospective analysis of the EXPRESS study,96 ADAS-cog items were further examined to determine the impact of rivastigmine on various cognitive domains. Patients receiving rivastigmine (3–12 mg/day) improved significantly on all three key symptom domains (memory [ P <0.001], language [ P =0.003] and praxis [ P =0.003]) compared with placebo at week 24; moreover, significant treatment differences with rivastigmine (3–12 mg/day) were observed on the following cognitive items: word recall, following commands, ideational praxis, remembering test instructions, and comprehension of spoken language ( P <0.05).…”
Section: Rivastigmine In Pddmentioning
“…No significant between‐group differences were observed at any time point in either the ITT [DB]‐OC or ‐LOCF analysis on the language domain. These data support previous analyses that demonstrate greater efficacy of rivastigmine on the memory domain compared with the language domain (Farlow et al ., ; Grossberg et al ., ; Schmitt et al ., ; Weintraub et al ., ).…”
Section: Discussionmentioning